Many gene therapeutic techniques havebeen developed, permittinglocal and extended cytokine production to decrease IL-12-induced toxicitiesfurther and enhance its efficiency in experimental tumor treatment.The IL-12 gene has been inserted into a variety of viral351−355 and nonviral356−358 vectors, into developing tumors,357,359−361 or into fibroblasts designed to expressIL-12 that have been injected at the location of an existing tumor.345 Vaccines containing tumor antigens,362 tumor cells,351,352 and dendriticcells363−365 have also been developed effectively usingthe IL-12 gene. This evidence concerns the gene SPRR2A and neoplasm.